comparemela.com

Shares of ACADIA Pharmaceuticals Inc. (ACAD) are down more than 18 percent in pre-market on Tuesday at $19.71, after its schizophrenia drug candidate failed to meet the primary endpoint in late-stage study.

Related Keywords

,Pharmaceuticals Inc ,Negative Symptom ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.